All In Biotech

Drug Trial Radar · NCT00989027

Impact of Uterotonic Agents on Isolated Human Myometrium

Last checked: Nov 20, 2026Latest source record: Feb 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Jun 2007

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the ability of a sample of uterine muscle tissue to contract in the presence of various drugs. The drugs studied are typically used to contract the uterus when a pregnant patient continues to bleed after delivery. Amongst the uterotonic drugs (used to contract the uterus), namely oxytocin, ergonovine and carboprost, the most effective one to use is not known. The investigators will be testing uterine muscle samples in the presence of these drugs at various concentrations, to see what their contractility measures over time, as compared with a control sample, in which no drugs will be applied.

Conditions

  • Postpartum Hemorrhage

Interventions

  • OxytocinDrug

    Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

  • ErgonovineDrug

    Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

  • CarboprostDrug

    Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

  • Oxytocin and ErgonovineDrug

    Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

  • Oxytocin and CarboprostDrug

    Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amplitude of contractionTime frame: 6-8 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.